Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion
Faeth Therapeutics, Inc FTH
$28.07
▲ +1.08%
(+$0.30)
Open
$27.77
Prev Close
$27.77
Day Range
$26.99 – $28.21
52W Range
$13.43 – $42.14
Market Cap
$725.34M
Beta
2.07
EPS (TTM)
$-141.65
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-04 |
| Shares Out. | 25,780,000 |
| Website | senseibio.com ↗ |
| Phone | 18008998648 |
| Employees | 29 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$16.0M |
| Free Cash Flow | -$33.9M |
| Total Assets | $189.3M |
| Total Liabilities | $9.6M |
| Equity | $173.0M |
About Faeth Therapeutics, Inc
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Faeth Therapeutics, Inc is a publicly traded company under the ticker symbol FTH on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-09-01)